| Literature DB >> 31602702 |
Viktória Koroknai1,2, István Szász1,2, Hector Hernandez-Vargas3, Nora Fernandez-Jimenez3, Cyrille Cuenin3, Zdenko Herceg3, Laura Vízkeleti1,2, Róza Ádány1,2, Szilvia Ecsedi1,2,3, Margit Balázs1,2.
Abstract
Tumor cell invasion is one of the key processes during cancer progression, leading to life-threatening metastatic lesions in melanoma. As methylation of cancer-related genes plays a fundamental role during tumorigenesis and may lead to cellular plasticity which promotes invasion, our aim was to identify novel epigenetic markers on selected invasive melanoma cells. Using Illumina BeadChip assays and Affymetrix Human Gene 1.0 microarrays, we explored the DNA methylation landscape of selected invasive melanoma cells and examined the impact of DNA methylation on gene expression patterns. Our data revealed predominantly hypermethylated genes in the invasive cells affecting the neural crest differentiation pathway and regulation of the actin cytoskeleton. Integrative analysis of the methylation and gene expression profiles resulted in a cohort of hypermethylated genes (IL12RB2, LYPD6B, CHL1, SLC9A3, BAALC, FAM213A, SORCS1, GPR158, FBN1 and ADORA2B) with decreased expression. On the other hand, hypermethylation in the gene body of the EGFR and RBP4 genes was positively correlated with overexpression of the genes. We identified several methylation changes that can have role during melanoma progression, including hypermethylation of the promoter regions of the ARHGAP22 and NAV2 genes that are commonly altered in locally invasive primary melanomas as well as during metastasis. Interestingly, the down-regulation of the methylcytosine dioxygenase TET2 gene, which regulates DNA methylation, was associated with hypermethylated promoter region of the gene. This can probably lead to the observed global hypermethylation pattern of invasive cells and might be one of the key changes during the development of malignant melanoma cells.Entities:
Keywords: DNA methylation; TET2; cell invasion; gene body; malignant melanoma
Mesh:
Substances:
Year: 2019 PMID: 31602702 DOI: 10.1111/exd.14047
Source DB: PubMed Journal: Exp Dermatol ISSN: 0906-6705 Impact factor: 3.960